Stephen Taub Premium Will M&A Cure Ailing Life Sciences Stocks? Hedge funds specializing in healthcare and biopharma are hoping that a surge in merger deals will jump-start their sickly performance. Stephen Taub August 17, 2022 T. Narayan/Bloomberg